The risks and benefits of therapy with aldosterone receptor antagonist therapy

Current Drug Safety

Volumn 2, Issue 1, 2007, Pages 71-77

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Aldosterone receptor antagonism; Eplerenone; Heart failure; Hyperkalemia; Resistant hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANRENONE; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LOSARTAN; MINERALOCORTICOID; PLACEBO; POTASSIUM ION; SAQUINAVIR; SODIUM ION; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ADD ON THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIURESIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE INHIBITION; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; KIDNEY TUBULE ABSORPTION; MEDICAL DECISION MAKING; MENSTRUAL IRREGULARITY; MONOTHERAPY; NATRIURESIS; OPTIMAL DRUG DOSE; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; SODIUM TRANSPORT; SURVIVAL RATE;

ALDOSTERONE ANTAGONISTS; ANIMALS; BREAST DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPERTENSION; RECEPTORS, ALDOSTERONE; RISK ASSESSMENT; WATER-ELECTROLYTE IMBALANCE;

EID: 34248217670     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607779315499     Document Type: Review

References (64)

1. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005; 10: 15-22.
2. Mihailidou AS. Nongenomic actions of aldosterone: physiological or pathophysiological role? Steroids 2006; 71: 277-280.
3. McInnes GT, Perkins RM, Shelton JR, Harrison IR. Spironolactone dose-response relationships in healthy subjects. Br J Clin Pharmacol 1982; 13: 513-518.
4. Shackleton CT, Wong NLM, Sutton RAL. Distal (potassium-sparing) diuretics. In: Diuretics: Physiology, Pharmacology, and Clinical Use. Dirks JH, Sutton RAL (eds) (1st edition) W.B. Saunders. 1986: 117-134.
5. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973; 225: 40-43.
6. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 27-31.
7. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52.
8. deGasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharm Exp Ther 1987; 240: 650-656.
9. Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005; 45: 810-821.
10. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-29.
11. Cook CS, Berry LM, Kim DH, et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Met Dispos 2002; 30: 1344-1351.
12. Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone coadministered with other medications. Pharmacotherapy 2002; 22: 1331.
13. Cook CS, Berry LM, Burton E. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 2004; 34: 215-228.
14. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-1265.
15. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003; 39: 187-192.
16. Ljubicic N, Kujundzic M, Banic M, Vrkljan M. Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. Scand J Gastroenterol 1998; 33: 441-447.
17. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979; 25: 33-42.
18. Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther 1980; 27: 533-543.
19. Henningsen NC. Single versus divided dose bioavailability of spironolactone in hypertensive patients. In Aldosterone Antagonists in Clinical Medicine, edited by Addison GM, Wirenfeldt Asmussen N, Corvol P. Kloppenborg PWC, Norman N, Schroder R, Robertson JIS, Excerpta Medica, Amsterdam, 1978, 227.
20. Weinberger MH. The use of selective aldosterone antagonists. Curr Hypertens Rep 2004; 6: 342-345.
21. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
22. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.
23. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716.
24. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006; 21: 854-858.
25. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46: 94-101.
26. McLaughlin N, Gehr TW, Sica DA. Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep 2004; 6: 327-330.
27. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
28. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.
29. Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19: 750-755.
30. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487.
31. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
32. Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002; 15(Suppl 1): A24.
33. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
34. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
35. Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475.
36. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
37. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006 Jun 14 [epub ahead of print].
38. Ogawa S, Takeuchi K, Mori T, Nako K, Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006; 33: 477-479.
39. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
40. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
41. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-842.
42. Pitt B, Rajagopalan S. Aldosterone receptor antagonists for heart failure: current status, future indications. Cleve Clin J Med 2006; 73: 257-60, 264-8.
43. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425-431.
44. Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
45. Krum H, Mohacsi P, Katus HA, et al. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J 2006; 151: 55-61.
46. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005; 112: 39-47.
47. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825.
48. Rose K, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Int Med 1977; 87: 398-403.
49. deGasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side-effects. J Steroid Biochem 1989; 32: 223-227.
50. Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006; 29: 149-53.
51. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure - a cautionary message. Br J Clin Pharmacol 2004; 58: 554-557.
52. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006; 333(7563): 330.
53. O'Connell JE, Colledge NR. Type IV renal tubular acidosis and spironolactone therapy in the elderly. Postgrad Med J 1993; 69: 887-889.
54. Sligl W, McAlister FA, Ezekowitz J, Armstrong PW. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol 2004; 94: 443-447.
55. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
56. Sica DA. Eplerenone and serum potassium change - relationship to renal function. Am J Hypertens 2003: 16(Suppl 1): A100.
57. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
58. Sica DA, Hess M. Aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Cong Heart Fail 2004; 10: 259-264.
59. Tamarisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004; 148: 971-978.
60. Blaustein DA, Babu K, Reddy A, et al. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol 2002; 90: 662-663.
61. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10: 297-303.
62. Ko DT, Juurlink DN, Mamdani MM, et al. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail 2006; 12: 205-210.
63. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005; 46: 845-849.
64. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41: 211-214.